FDA grants Orphan Drug Designation to PYC

On the 24/5/2024 PYC was granted Orphan Drug Designation for the ADOA drug

It was my understanding that the ADOA drug progress through human trials etc was actually 6/12 months behind RP 11

The fact that ADOA has already achieved that special status is most interesting, but does it mean that RP 11 was unable to qualify in the early days?

Is there still any possibility of RP 11 still getting that ODD status? and if so, at would point of the trials cycle do they get awarded?

Also, is this the certificate worth US$100 million bonus if the drugs are successful in the trials and approved by FDA for commerciality?

Would appreciate the views of those who understand the FDA system